Genomic profiling in gynaecological oncology: the future is now!

Nowadays, thanks to next generation sequencing, it is simultaneously possible to search for driver mutations in hundreds of cancer-related genes with high sensibility and specificity, by exploiting formalin-fixed paraffin-embedded tumor material, from biopsy samples and surgical specimens, or circulating tumor DNA in the patient’s blood. In addition to indicate the genomic alterations, this modern technology provides information about: the approved therapies in the patient’s cancer type or in other tumor types for a personalized oncology; potential clinical trials; mutational burden and microsatellite instability (MSI). This last datum is particularly relevant because the U.S. Food & Drug AdministratiNowadays, thanks to next generation sequencing, it is simultaneously possible to search for driver mutations in hundreds of cancer-related genes with high sensibility and specificity, by exploiting formalin-fixed paraffin-embedded tumor material, from biopsy samples and surgical specimens, or circulating tumor DNA in the patient's blood. In addition to indicate the genomic alterations, this modern technology provides information about: the approved therapies in the patient’s cancer type or in other tumor types for a personalized oncology; potential clinical trials; mutational burden and microsatellite instability (MSI). This last datum is particularly relevant because the U.S. Food & Drug Administration (FDA) has approved the use of pembrolizumab for all unresectable or metastatic, MSI-high or mismatch repair deficient, solid malignancies, among which there are 17-32% of sporadic endometrial carcinomas and 10-17% of sporadic ovarian cancers. Similarly, the FDA has approved olaparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, characterized by deleterious or suspected deleterious germline or somatic mutations in ‘breast cancer’ (BRCA) genes, who are in complete or partial response to first-line platinum-based chemotherapy. Therefore, we are facing an era of innovation in gynaecological oncology, in which molecular profiling is joining immunomorphological typing for new health goals.

Next generation sequencing (NGS); Microsatellite instability (MSI); Mismatch repair (MMR); Breast cancer (BRCA) genes; Pembrolizumab; Olaparib

[1] Dulbecco R.: “A turning point in cancer research: sequencing the human genome”. Science, 1986, 231, 1055.

[2] Collins F.S., Morgan M., Patrinos A.: “The Human Genome Project: lessons from largescale biology”. Science, 2003, 300, 286.

[3] Covell D.G.: “Data mining approaches for genomic biomarker development: applications using drug screening data from the Can-cer Genome Project and the Cancer Cell Line Encyclopedia”. PLoS One, 2015, 10, e0127433.

[4] Strausberg R.L., Simpson A.J., Old L.J., Riggins G.J.: “Oncogenomics and the development of new cancer therapies”. Nature, 2004, 429, 469.

[5] Roncati L., Simoni M., Maiorana A.: “The prognostic value of miRNA146a in follicular thyroid carcinoma”. Med. Oncol., 2013, 30, 703.

[6] Roncati L., Barbolini G., Sartori G., Siopis E., Pusiol T., Maiorana A.: “Loss of CDKN2A promoter methylation coincides with the epi-genetic transdifferentiation of uterine myosarcomatous cells”. Int. J. Gynecol. Pathol., 2016, 35, 309.

[7] Krontiris T.G.: “Oncogenes”. N. Engl. J. Med., 1995, 333, 303.

[8] Frampton G.M., Fichtenholtz A., Otto G.A., Wang K., Downing S. R., He J., et al.: “Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequenc-ing”. Nat. Biotechnol., 2013, 31, 1023.

[9] He J., Abdel-Wahab O., Nahas M.K., Wang K., Rampal R.K., Intlekofer A.M., et al.: “Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting”. Blood, 2016, 127, 3004.

[10] U.S. Food & Drug Administration. Resources for Information on Approved Drugs. Silver Spring, MD: U.S. Food & Drug Administration; 2017 [accessed 2017 May 30]. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication.

[11] Karamurzin Y., Rutgers J.K.: “DNA mismatch repair deficiency in endometrial carcinoma”. Int. J. Gynecol. Pathol., 2009, 28, 239.

[12] Murali R., Soslow R.A., Weigelt B.: “Classification of endometrial carcinoma: more than two types”. Lancet Oncol., 2014, 15, e268.

[13] Singer G., Kallinowski T., Hartmann A., Dietmaier W., Wild P.J., Schraml P., et al.: “Different types of microsatellite instability in ovarian carcinoma”. Int. J. Cancer, 2004, 112, 643.

[14] Shannon C., Kirk J., Barnetson R., Evans J., Schnitzler M., Quinn M., et al.: “Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium”. Clin. Cancer Res., 2003, 9, 1387.

[15] Kobayashi H., Ohno S., Sasaki Y., Matsuura M.: “Hereditary breast and ovarian cancer susceptibility genes (review)”. Oncol. Rep., 2013, 30, 1019.

[16] U.S. Food & Drug Administration. Drugs. Silver Spring, MD: U.S. Food & Drug Administration; 2018 [accessed 2018 Dec 26]. Available at: https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients.

[17] Roncati L., Barbolini G., Piacentini F., Piscioli F., Pusiol T., Maiorana A.: “Prognostic factors for breast cancer: an immunomorpho-logical update”. Pathol. Oncol. Res., 2016, 22, 449.

[18] III Convegno Oncologia Integrata. Genetica e medicina integrata in oncologia e psiconcologia: come utilizzare la mappa del nostro DNA per traguardi di prevenzione e salute. Modena, IT: Forum Monzani; 2019 [accessed 2019 Mar 3]. Available at: https://www.convegnoncologiaintegrata.it.

[19] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2019”. CA Cancer J. Clin., 2019, 69, 7.